Bosutinib

Bosutinib (BosulifÒ, Pfizer Europe), a second generation TKI, was created for patients unresponsive or intolerant to imatinib, nilotinib or dasatinib.

Bosutinib is approved for:

  • Patients with newly‑diagnosed CML
  • Patients previously treated with one or more TKIs
  • Patients in whom imatinib, nilotinib and dasatinib are not appropriate
Scroll to Top